Integra Lifesciences Holdings Corp IART
We take great care to ensure that the data presented and summarized in this overview for INTEGRA LIFESCIENCES HOLDINGS CORP is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IART
View all-
Black Rock Inc. New York, NY11.3MShares$220 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.77MShares$152 Million0.0% of portfolio
-
Morgan Stanley New York, NY5.5MShares$107 Million0.01% of portfolio
-
Eaton Vance Management Boston, MA4.22MShares$82.2 Million0.26% of portfolio
-
Wellington Management Group LLP Boston, MA3.89MShares$75.8 Million0.02% of portfolio
-
Cooke & Bieler LP3.51MShares$68.6 Million1.07% of portfolio
-
Alliancebernstein L.P. New York, NY3.09MShares$60.3 Million0.03% of portfolio
-
State Street Corp Boston, MA2.78MShares$54.2 Million0.0% of portfolio
-
Capital Research Global Investors Los Angeles, CA2.43MShares$47.4 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA2.03MShares$39.6 Million0.01% of portfolio
Latest Institutional Activity in IART
Top Purchases
Top Sells
About IART
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.
Insider Transactions at IART
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 01
2024
|
Chantal Veillon Berteloot EVP & CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,412
-5.47%
|
$28,240
$20.34 P/Share
|
Aug 19
2024
|
Jeffrey Mosebrook SVP, Fin & Princ Acct Officer |
SELL
Open market or private sale
|
Direct |
1,191
-3.19%
|
$25,011
$21.58 P/Share
|
Jul 03
2024
|
Lea Daniels Knight EVP & CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
2,561
-5.76%
|
$71,708
$28.73 P/Share
|
Jul 01
2024
|
Jeffrey Mosebrook SVP, Fin & Princ Acct Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,356
+21.74%
|
-
|
May 23
2024
|
Stuart Essig Exec. Chairman of the Board |
BUY
Open market or private purchase
|
Direct |
52,641
+9.74%
|
$1,473,948
$28.49 P/Share
|
May 21
2024
|
Barbara B Hill Director |
BUY
Open market or private purchase
|
Indirect |
36,350
+50.0%
|
$981,450
$27.4 P/Share
|
May 12
2024
|
Keith Bradley Director |
SELL
Payment of exercise price or tax liability
|
Direct |
239
-0.17%
|
$5,975
$25.99 P/Share
|
May 09
2024
|
Stuart Essig Exec. Chairman of the Board |
BUY
Grant, award, or other acquisition
|
Direct |
13,835
+0.73%
|
-
|
May 09
2024
|
Barbara B Hill Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,859
+5.66%
|
-
|
May 09
2024
|
Jeffrey A Graves Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,278
+35.22%
|
-
|
May 09
2024
|
Shaundra Clay Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,696
+28.4%
|
-
|
May 09
2024
|
Renee Wonlai Lo Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,696
+35.0%
|
-
|
May 09
2024
|
Raymond G. Murphy Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,696
+13.87%
|
-
|
May 09
2024
|
Christian S Schade Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,696
+12.04%
|
-
|
May 09
2024
|
Keith Bradley Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,696
+11.03%
|
-
|
Mar 12
2024
|
Robert T. Davis Jr. EVP & President, TT |
SELL
Payment of exercise price or tax liability
|
Direct |
2,024
-1.52%
|
$70,840
$35.88 P/Share
|
Mar 12
2024
|
Jeffrey Mosebrook SVP, Fin & Princ Acct Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
347
-0.64%
|
$12,145
$35.88 P/Share
|
Mar 12
2024
|
Eric Schwartz EVP, Chief Legal Officer & Sec |
SELL
Payment of exercise price or tax liability
|
Direct |
1,438
-1.11%
|
$50,330
$35.88 P/Share
|
Mar 12
2024
|
Michael J. Mc Breen EVP & President, CSS |
SELL
Payment of exercise price or tax liability
|
Direct |
2,012
-1.69%
|
$70,420
$35.88 P/Share
|
Mar 11
2024
|
Robert T. Davis Jr. EVP & President, TT |
BUY
Grant, award, or other acquisition
|
Direct |
20,283
+13.94%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 195K shares |
---|---|
Open market or private purchase | 89K shares |
Exercise of conversion of derivative security | 20.9K shares |
Payment of exercise price or tax liability | 27.6K shares |
---|---|
Open market or private sale | 9.54K shares |